A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non–Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade

• Published in: Clinical lung cancer Vol. 23; no. 7; pp. e400 - e404
• Main Authors: Osta, Badi El, Carlisle, Jennifer, Steuer, Conor, Pakkala, Suchita, Leal, Ticiana, Dhodapkar, Madhav, Liu, Yuan, Chen, Zhengjia, Owonikoko, Taofeek, Ramalingam, Suresh
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2022
• Subjects: Anti-angiogenic; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung - pathology; Chemotherapy; Docetaxel - therapeutic use; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Lung Neoplasms - pathology; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - etiology; Non-small cell lung cancer; Phase 2; Platinum - therapeutic use; Programmed Cell Death 1 Receptor; Ramucirumab; Chemotherapy; Phase 2; Anti-angiogenic; Immunotherapy; Non-small cell lung cancer

There is an urgent and unmet need for more effective treatment options for patients with metastatic and recurrent non–small-cell lung cancer (NSCLC) who progressed on platinum-based therapy, immune checkpoint inhibitors (ICI), and targeted therapies. Currently, the combination of docetaxel (D) and r...